These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 37830609)

  • 1. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
    Haque US; Yokota T
    Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
    Leckie J; Yokota T
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review.
    Nakevska Z; Yokota T
    Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
    Shadid M; Badawi M; Abulrob A
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
    Lim KRQ; Woo S; Melo D; Huang Y; Dzierlega K; Shah MNA; Aslesh T; Roshmi RR; Echigoya Y; Maruyama R; Moulton HM; Yokota T
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35193974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.
    Stoodley J; Miraz DS; Jad Y; Fischer M; Wood MJA; Varela MA
    Methods Mol Biol; 2023; 2587():209-237. PubMed ID: 36401033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide.
    Yeoh YQ; Amin A; Cuic B; Tomas D; Turner BJ; Shabanpoor F
    Biomed Pharmacother; 2024 Jun; 175():116737. PubMed ID: 38749176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.
    Shabanpoor F; McClorey G; Saleh AF; Järver P; Wood MJ; Gait MJ
    Nucleic Acids Res; 2015 Jan; 43(1):29-39. PubMed ID: 25468897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
    Hammond SM; Abendroth F; Gait MJ; Wood MJA
    Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration.
    Aslesh T; Erkut E; Ren J; Lim KRQ; Woo S; Hatlevig S; Moulton HM; Gosgnach S; Greer J; Maruyama R; Yokota T
    JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36719755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.
    Shabanpoor F; Hammond SM; Abendroth F; Hazell G; Wood MJA; Gait MJ
    Nucleic Acid Ther; 2017 Jun; 27(3):130-143. PubMed ID: 28118087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment.
    Gait MJ; Arzumanov AA; McClorey G; Godfrey C; Betts C; Hammond S; Wood MJA
    Nucleic Acid Ther; 2019 Feb; 29(1):1-12. PubMed ID: 30307373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 18. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing.
    Le BT; Paul S; Jastrzebska K; Langer H; Caruthers MH; Veedu RN
    Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2207956119. PubMed ID: 36037350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helix-Stabilized Cell-Penetrating Peptides for Delivery of Antisense Morpholino Oligomers: Relationships among Helicity, Cellular Uptake, and Antisense Activity.
    Takada H; Tsuchiya K; Demizu Y
    Bioconjug Chem; 2022 Jul; 33(7):1311-1318. PubMed ID: 35737901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.